while in the speedily evolving area of oncology exploration, exact and economical mutation screening is critical for creating specific therapies. The KRAS solutions System plays a pivotal part in this landscape by featuring in depth alternatives for KRAS mutation profiling and analysis. KRAS mutations, present in about ninety five% of RAS-associate